甲氨蝶呤单药与联合低剂量泼尼松治疗全秃或普秃的疗效:两步双盲随机临床试验
这项多中心双盲随机试验纳入89例慢性顽固性全秃或普秃成人患者,比较甲氨蝶呤单药与安慰剂6个月,未达25%毛发再生者再随机接受甲氨蝶呤联合泼尼松或安慰剂。第12个月时,甲氨蝶呤联合泼尼松组有20.0%的患者达到完全或几乎完全毛发再生,甲氨蝶呤单药组仅1例,安慰剂组0例;联合治疗可使高达31.2%的患者获得完全再生。
要点
- 甲氨蝶呤单药治疗慢性全秃或普秃仅能使部分患者获得部分毛发再生。
- 甲氨蝶呤联合低剂量泼尼松可使20.0%患者达到完全或几乎完全毛发再生。
- 未观察到严重治疗不良事件,2例因疲劳和恶心退出。
核心结论
- 在慢性全秃或普秃患者中,甲氨蝶呤单药主要引起部分毛发再生,而联合低剂量泼尼松可使高达31%的患者获得完全毛发再生。
- 这些结果似乎与近期报道的JAK抑制剂处于相同数量级,但成本低得多。
研究设计与样本
- 学术性、多中心、双盲、随机临床试验,在8个大学医院皮肤科开展,时间为2014年3月至2016年12月。
- 纳入89例成人全秃或普秃患者(全秃1例,普秃88例),病程超过6个月且既往局部和系统治疗无效。
- 患者随机接受甲氨蝶呤25 mg/周或安慰剂治疗6个月;第6个月毛发再生大于25%者继续治疗至12个月,小于25%者再次随机接受甲氨蝶呤联合泼尼松(20 mg/d用3个月,15 mg/d用3个月)或甲氨蝶呤联合泼尼松安慰剂。
主要发现
- 第12个月时,甲氨蝶呤单药组有1例、安慰剂组有0例达到完全或几乎完全毛发再生(SALT评分<10)。
- 接受甲氨蝶呤(6或12个月)联合泼尼松的患者中,7/35(20.0%;95%CI 8.4%-37.0%)达到完全或几乎完全毛发再生。
- 其中接受甲氨蝶呤12个月联合泼尼松6个月的患者中,5/16(31.2%;95%CI 11.0%-58.7%)达到完全或几乎完全毛发再生。
- 达到完全缓解的患者生活质量改善大于未缓解患者。
- 甲氨蝶呤组有2例因疲劳和恶心退出研究;接受甲氨蝶呤的患者中分别有7例(6.9%)和14例(13.7%)观察到疲劳和恶心;未观察到严重治疗不良事件。
关键数值与推荐
- 主要终点为第12个月时通过照片由4位国际专家评估的完全或几乎完全毛发再生(SALT评分<10)。
- 次要终点包括主要毛发再生率(大于50%)、生活质量和治疗耐受性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Poor therapeutic results have been reported in patients with alopecia areata totalis (AT) or universalis (AU), the most severe and disabling types of alopecia areata (AA). Methotrexate, an inexpensive treatment, might be effective in AU and AT. OBJECTIVE: To evaluate the efficacy and tolerance of methotrexate alone or combined with low-dose prednisone in patients with chronic and recalcitrant AT and AU. DESIGN, SETTING, AND PARTICIPANTS: This academic, multicenter, double-blind, randomized clinical trial was conducted at 8 dermatology departments at university hospitals between March 2014 and December 2016 and included adult patients with AT or AU evolving for more than 6 months despite previous topical and systemic treatments. Data analysis was performed from October 2018 to June 2019. INTERVENTIONS: Patients were randomized to receive methotrexate (25 mg/wk) or placebo for 6 months. Patients with greater than 25% hair regrowth (HR) at month 6 continued their treatment until month 12. Patients with less than 25% HR were rerandomized: methotrexate plus prednisone (20 mg/d for 3 months and 15 mg/d for 3 months) or methotrexate plus placebo of prednisone. MAIN OUTCOME AND MEASURES: The primary end point assessed on photos by 4 international experts was complete or almost complete HR (Severity of Alopecia Tool [SALT] score <10) at month 12, while receiving methotrexate alone from the start of the study. Main secondary end points were the rate of major (greater than 50%) HR, quality of life, and treatment tolerance. RESULTS: A total of 89 patients (50 female, 39 male; mean [SD] age, 38.6 [14.3] years) with AT (n = 1) or AU (n = 88) were randomized: methotrexate (n = 45) or placebo (n = 44). At month 12, complete or almost complete HR (SALT score <10) was observed in 1 patient and no patient who received methotrexate alone or placebo, respectively, in 7 of 35 (20.0%; 95% CI, 8.4%-37.0%) patients who received methotrexate (for 6 or 12 months) plus prednisone, including 5 of 16 (31.2%; 95% CI, 11.0%-58.7%) who received methotrexate for 12 months and prednisone for 6 months. A greater improvement in quality of life was observed in patients who achieved a complete response compared with nonresponder patients. Two patients in the methotrexate group discontinued the study because of fatigue and nausea, which were observed in 7 (6.9%) and 14 (13.7%) patients receiving methotrexate, respectively. No severe treatment adverse effect was observed. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, while methotrexate alone mainly allowed partial HR in patients with chronic AT or AU, its combination with low-dose prednisone allowed complete HR in up to 31% of patients. These results seem to be of the same order of magnitude as those recently reported with JAK inhibitors, with a much lower cost. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02037191.
引用
- Joly P, Lafon A, Houivet E, et al. Efficacy of Methotrexate Alone vs Methotrexate Plus Low-Dose Prednisone in Patients With Alopecia Areata Totalis or Universalis: A 2-Step Double-Blind Randomized Clinical Trial. JAMA Dermatol. 2023. PMID: 36884234. doi:10.1001/jamadermatol.2022.6687
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。